Valueinvest Asset Management S.A. grew its holdings in Pfizer (NYSE:PFE) by 2.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,345,100 shares of the biopharmaceutical company’s stock after purchasing an additional 119,300 shares during the quarter. Pfizer makes up approximately 9.7% of Valueinvest Asset Management S.A.’s holdings, making the stock its 6th biggest holding. Valueinvest Asset Management S.A. owned about 0.07% of Pfizer worth $157,380,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Beach Investment Management LLC. bought a new position in Pfizer during the 2nd quarter worth approximately $5,214,000. Hanson McClain Inc. boosted its stake in Pfizer by 2.0% during the 2nd quarter. Hanson McClain Inc. now owns 13,898 shares of the biopharmaceutical company’s stock worth $467,000 after acquiring an additional 276 shares during the last quarter. Alpha Omega Wealth Management LLC boosted its stake in Pfizer by 3.4% during the 2nd quarter. Alpha Omega Wealth Management LLC now owns 108,815 shares of the biopharmaceutical company’s stock worth $3,655,000 after acquiring an additional 3,534 shares during the last quarter. Usca Ria LLC boosted its stake in Pfizer by 0.3% during the 2nd quarter. Usca Ria LLC now owns 332,964 shares of the biopharmaceutical company’s stock worth $11,184,000 after acquiring an additional 1,033 shares during the last quarter. Finally, Intrust Bank NA boosted its stake in Pfizer by 2.5% during the 2nd quarter. Intrust Bank NA now owns 65,268 shares of the biopharmaceutical company’s stock worth $2,192,000 after acquiring an additional 1,596 shares during the last quarter. 71.19% of the stock is currently owned by institutional investors.
Shares of PFE stock opened at $36.63 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. The company has a market cap of $217,458.14, a price-to-earnings ratio of 13.82, a P/E/G ratio of 1.83 and a beta of 0.90. Pfizer has a 52 week low of $31.67 and a 52 week high of $39.43.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a net margin of 40.55% and a return on equity of 25.21%. The company had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. During the same period last year, the company earned $0.47 earnings per share. The firm’s revenue was up .6% compared to the same quarter last year. analysts forecast that Pfizer will post 2.95 EPS for the current year.
In other news, insider Mikael Dolsten sold 69,699 shares of Pfizer stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $36.59, for a total value of $2,550,286.41. Following the sale, the insider now directly owns 120,784 shares in the company, valued at $4,419,486.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director W Don Cornwell sold 1,758 shares of Pfizer stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the sale, the director now owns 1,000 shares in the company, valued at $36,790. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock worth $9,064,785 over the last quarter. 0.06% of the stock is owned by corporate insiders.
Several research firms recently weighed in on PFE. Sanford C. Bernstein set a $43.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Goldman Sachs set a $36.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, January 30th. UBS set a $42.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Wednesday, January 31st. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a research note on Tuesday, January 30th. Finally, Zacks Investment Research raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research note on Wednesday, April 11th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the stock. Pfizer currently has an average rating of “Hold” and an average target price of $39.20.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/22/pfizer-pfe-is-valueinvest-asset-management-s-a-s-6th-largest-position.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.